Monitor upcoming clinical data readouts (KLARITY late 2026, ABACUS-2 topline Q3 2027) and any strategic transaction announcements that could trigger warrant exercises. The private placement provides near-term funding but dilutes existing shareholders.
Price Chart
Executive Summary
Kiora Pharmaceuticals reported Q2 2026 net loss of $2.1M ($0.34 per share), improved from $2.2M ($0.54) in Q2 2025, with cash and short-term investments of $16.8M providing runway into late 2028. The company advanced enrollment in both Phase 2 trials (ABACUS-2 for KIO-301, KLARITY for KIO-104) and secured a private placement for up to $24M in gross proceeds, including $5M upfront. No revenue or analyst consensus was provided; the filing is routine for a clinical-stage biotech.
Key Financial Metrics
Key Facts
- Cash and short-term investments of $16.8M at June 30, 2026, up from $13.9M at March 31, 2026
- Net loss of $2.1M for Q2 2026 vs $2.2M in Q2 2025
- EPS of $(0.34) vs $(0.54) year-over-year, aided by higher share count (6.18M vs 3.99M)
- Private placement secured for up to $24M in gross proceeds, $5M received upfront
- Phase 2 ABACUS-2 trial of KIO-301 advanced to higher-dose cohort; topline data expected Q3 2027
- Phase 2 KLARITY trial of KIO-104 enrolling higher-dose cohort; initial data expected late 2026
- Operating runway expected into late 2028
Financial Impact
Net loss improved ~5% YoY; cash increased ~21% QoQ from equity financing
Risk Factors
- Dilution from private placement warrants if exercised
- Clinical trial delays or negative data
- No revenue and reliance on partnership reimbursements
- Potential failure to complete strategic transaction
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001372514-26-000075 |
| Document: kprx-20260807.htm | 0001372514-26-000075 |
| Document: 0001372514-26-000075-index-headers.html | 0001372514-26-000075 |
| Document: 0001372514-26-000075-index.html | 0001372514-26-000075 |
| Document: 0001372514-26-000075.txt | 0001372514-26-000075 |
| 8-K Data (Synthetic) | 0001372514-26-000075 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 8, 2026 7w ago | 8-K | $2.51 $2.50 | ▼ −0.40% | ▼ −2.37% | $2.30 (−8.37%) |
Aug 19, 2026 9w ago | 8-K | $2.60 $2.67 | ▲ +2.69% | ▲ +4.64% | $2.30 (−11.54%) |
Aug 7, 2026 11w ago | 8-K | $2.64 $2.55 | ▼ −3.41% | ▼ −3.01% | $2.30 (−12.88%) |
Jun 18, 2026 18w ago | 8-K | $2.53 $2.55 | ▲ +0.79% | ▲ +0.26% | $2.30 (−9.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers